T. Rowe Price Investment Management (IMNM) discloses 17.4% Immunome ownership, key fund at 6.5%
Rhea-AI Filing Summary
T. Rowe Price Investment Management, Inc. reports beneficial ownership of 19,676,883 shares of Immunome, Inc. common stock, representing 17.4% of the class. It has sole voting power over 19,656,814 shares and sole dispositive power over 19,676,883 shares, with no shared voting or dispositive power.
The shares are held for advisory clients, who retain the right to receive dividends and sale proceeds, and may revoke delegated authority. The T. Rowe Price Small-Cap Stock Fund has an interest in 7,179,563 shares, representing 6.5% of Immunome’s common stock. T. Rowe Price Investment Management expressly denies beneficial ownership beyond this reporting capacity.
Positive
- None.
Negative
- None.
Key Figures
Shares beneficially owned: 19,676,883 shares
Percent of class: 17.4%
Sole voting power: 19,656,814 shares
+3 more
6 metrics
Shares beneficially owned
19,676,883 shares
Immunome Inc common stock reported as beneficially owned by T. Rowe Price Investment Management, Inc.
Percent of class
17.4%
Portion of Immunome Inc common stock class attributed to T. Rowe Price Investment Management, Inc.
Sole voting power
19,656,814 shares
Shares of Immunome Inc over which T. Rowe Price Investment Management, Inc. has sole power to vote
Sole dispositive power
19,676,883 shares
Shares of Immunome Inc over which T. Rowe Price Investment Management, Inc. has sole power to dispose
Small-Cap Stock Fund holdings
7,179,563 shares
Immunome Inc shares held by T. Rowe Price Small-Cap Stock Fund advised by T. Rowe Price Investment Management, Inc.
Small-Cap Stock Fund percent of class
6.5%
Portion of Immunome Inc common stock class held by T. Rowe Price Small-Cap Stock Fund
Key Terms
beneficially owned, sole voting power, sole dispositive power, Investment Company Act of 1940, +1 more
5 terms
beneficially owned financial
"Amount beneficially owned: 19676883"
Beneficially owned describes securities or assets where a person has the economic rights and control—such as the right to receive dividends and to direct voting—even if legal title is held in another name. Think of it like having the keys and using a car that’s registered to someone else: you get the benefits and make decisions. Investors care because beneficial ownership reveals who truly controls value and voting power, affecting corporate decisions and takeover dynamics.
sole voting power financial
"Sole power to vote or to direct the vote: 19656814"
Sole voting power is the exclusive right to cast votes attached to a shareholder’s stock without needing approval from anyone else. Like holding the only remote control for a TV, it lets that holder decide corporate matters such as board members, mergers, and policy changes, making it important to investors because it concentrates control and can strongly influence a company’s strategy and the value of its shares.
sole dispositive power financial
"Sole power to dispose or to direct the disposition of: 19676883"
Sole dispositive power is the exclusive legal authority to decide what happens to a security — for example, whether to sell, transfer, or retain shares — without needing anyone else’s permission. Investors care because it signals who truly controls the economic outcome of an investment: like holding the only key to a safe, the holder can realize gains or losses and may trigger regulatory reporting, insider rules, or influence over corporate ownership.
Investment Company Act of 1940 regulatory
"investment company registered under the Investment Company Act of 1940"
A U.S. federal law that sets the rulebook for pooled investment vehicles such as mutual funds, exchange-traded funds and similar money managers, requiring them to register with regulators, disclose holdings and fees, limit conflicts of interest, and follow governance standards. It matters to investors because these protections and transparency rules act like a referee and scoreboard, helping people compare funds, trust that managers follow fair practices, and spot hidden costs or risks.
discretionary authority financial
"Any and all discretionary authority which has been delegated"
FAQ
What percentage of Immunome Inc (IMNM) does T. Rowe Price Investment Management report owning?
T. Rowe Price Investment Management, Inc. reports beneficial ownership of 17.4% of Immunome Inc’s common stock, representing 19,676,883 shares over which it has sole dispositive power and substantial sole voting power on behalf of its advisory clients.
What is the Immunome Inc (IMNM) stake of the T. Rowe Price Small-Cap Stock Fund?
The T. Rowe Price Small-Cap Stock Fund has an interest in 7,179,563 Immunome Inc shares, representing 6.5% of the common stock class. T. Rowe Price Investment Management serves as investment adviser to this fund and manages these holdings.
Who ultimately receives dividends and sale proceeds from T. Rowe Price’s Immunome Inc (IMNM) holdings?
Dividends and sale proceeds from the Immunome Inc shares are received by clients or their custodians, not by T. Rowe Price Investment Management. The ultimate power to direct receipt rests with individual and institutional clients it advises.
Does T. Rowe Price Investment Management claim full beneficial ownership of its Immunome Inc (IMNM) shares?
No. T. Rowe Price Investment Management expressly denies beneficial ownership of the Immunome Inc securities beyond its role as investment adviser. It states that clients, not the adviser, ultimately benefit from dividends and sale proceeds.
AI-generated analysis. How Rhea-AI works. Not financial advice.